Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SC291 |
| Synonyms | |
| Therapy Description |
SC291 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19, which may induce a cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SC291 | SC 291|SC-291|Allogeneic HIP Anti-CD19 CAR-T Cells SC291 | CD19 Immune Cell Therapy 72 | SC291 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19, which may induce a cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |